News for Nurix Therapeutics, Inc. (NRIX)

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025

**media[597931]**

Nurix Therapeutics (NRIX) granted inducement awards to 16 new employees as part of their 2024 Equity Inducement Plan. The awards comprise stock options

**media[592903]**

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 6.94% and 26.41%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

**media[589629]**

Summary: Nurix Therapeutics (NRIX) stocks surge following a new licensing agreement with Sanofi.The collaborative venture focuses on an undisclosed molecule rel

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

**media[583680]**

**media[576531]**

Nurix Therapeutics Inc (NRIX), a clinical-stage biopharmaceutical company, announced on March 17, 2025, that the U.S. Food and Drug Administration (FDA) has gra

**media[568256]**

SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( NRIX), a clinical-stage biopharmaceutical company focused on the discovery, devel

Dr. Baynes has been a member of Nurix's Medical Advisory Board since 2023 SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( NRI

**media[566072]**

Nurix Therapeutics Inc (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, announced on March 4, 2025, th

SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( NRIX), a clinical-stage biopharmaceutical company focused on the discovery, devel

On March 3, 2025, Houte Van, the Chief Financial Officer of Nurix Therapeutics Inc, executed a sale of 5,825 shares of the company. Following this transaction,

Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of KYMR stock now.